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Interferon β is attracting attention as an anticancer drug because it can induce the 
death of cancer cells. However, low stability of interferon β, induction of systemic 
toxicity after administration, and resistance of cancer cells are limiting the use of 
interferon β as an anticancer agent. 
In the previous study, we have developed rhIFNβ-1a, which induces additional 
glycosylation of its 25 amino acid by substituting Threonine for arginine, the 27th 
amino acid of recombinant human interferon β 1a (rhIFNβ-1a) and named R27T. We 
also developed a fusion protein of R27T that was fused to the anti-ERBB-2 
therapeutic antibody, Trastuzumab. In addition, Trastuzumab-C17S-R27T, in which 
ii 
amino acid cysteine at position 17 of rhIFNβ-1a was replaced with serine, was 
developed to further improve physical properties and efficacy. 
This study was conducted to compare the purification efficiency and biological 
properties of Trastuzumab-R27T and Trastuzumab-C17S-R27T in the purification 
using affinity chromatography and ion exchange chromatography. The interferon 
bioactivity, immunomodulatory effect, anticancer efficacy, ability to bind to HER2, 
and ADCC efficacy were also compared. 
Trastuzumab-C17S-R27T showed improved purification efficiency and decreased 
aggregation in terms of physical properties when compared with Trastuzumab -R27T. 
It also confirmed that anti-cancer effect, interferon bioactivity and 
immunomodulatory efficacy were the same. In addition, the ability to bind HER2, 
and ADCC efficacy, was similar to Trastuzumab-R27T. 
 
Therefore, Trastuzumab-C17S-R27T, which replaced cysteine with Serine, was 
found to be a more effective anticancer drug than Trastuzumab-R27T. 
 
Key words: Interferon, Trastuzumab-C17S-R27T, Immunotherapy, Antibody, 
Anticancer, Fusion protein 
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1. The role of interferons 
Interferon is one of the major cytokines that play a role in immunity and has 
several potent anti-cancer effects in table 1. They are divided into type 1 (α and β 
interferons) and type 2 (γ or immune interferon). 
 Type 1 interferons, where β interferons belong, have potent antiviral activity and 
are produced mainly by fibroblasts and monocytes as a reaction to infection. Both α 
and β interferon bind to the same cellular receptor and protect uninfected cells by 
inducing the intracellular production of molecules that inhibit or interfere with viral 
RNA and DNA production. They increase the expression of MHC class I molecules 
leading to enhanced recognition of virally infected cells by specific cytotoxic T 
lymphocytes. Type 1 interferons also have antiproliferative function. β interferon 
reduces the relapse rate in subgroups of patients with multiple sclerosis. Interferon β 
has different functions, acting directly on the immune system to activate macrophage 
and neutrophil intracellular killing, stimulate natural killer cell function, and enhance 
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IFN-α/β + + + + + + Approved 
IFN-γ + +/− + + + +/− Approved 
IL-2 + − + − − + Approved 
IL-7 + − − − − − Phase I, II 
IL-12 + − + − +/− +/− Phase I, II 
IL-15 + − + − − − Phase I, II 
IL-18 + − + − +/− − Phase I, II 
IL-21 + − + +/− − +/− Phase I, II 
GM-CSF + + +/− − − + Approved 
TNFα–1a +/− +/− − − + +/− Approved 
 
３ 
Beyond their role in curtailing viral infection, type I IFNs play an essential part in  
natural cancer immunosurveillance, functioning both at the level of malignant cell 
precursors and through effects on the immune system.  
Type I IFN signalling is also essential for the full-blown efficacy of various 
anticancer agents, including chemotherapeutics (such as anthracyclines), antibodies 
that target growth factor receptors (such as human epidermal growth factor receptor 
2 (HER2) and epidermal growth factor receptor (EGFR)), the injection of adjuvants 
and oncolytic virotherapy. [2] In particular, Trastuzumab, which targets HER2, is 
resistant to overexpression of MUC4. This is because MUC4 prevents Trastuzumab 
from attaching to HER2. [3] One of the signals involved in this resistance mechanism 
is the homodimer of pSTAT3. [4] It is known that pSTAT3 is a homodimer that is 
cross regulation by pSTAT1. [5] Therefore, we believe that binding the substance 
that induces the pSTAT1 signal to trastuzumab would overcome resistance. The 
pSTAT1 signal is known to be triggered by type I and II interferons, among which 
antibodies have been developed that combine Trastuzumab with type I interferons 
with multiple anti-cancer effects. 
 
2. Limitation of interferon β 
IFN-β was more potent than IFN-α in inhibiting the cell growth of various cell 
lines. The spectra of the antiproliferative activity and synergistic effect of IFN-β 
when combined with anticancer drugs are more potent than those of IFN-α. 
４ 
Combinations of IFN-β and anticancer drugs may provide a better treatment for HCC 
and other cancers when combinations with IFN-α are ineffective.[6] 
Unfortunately, IFN therapy is associated with significant toxicity, which can be 
divided into the five most frequently occurring symptoms being fever (80%), 
myalgia (73%), headache (50%), fatigue (50%) and malaise (50%). [7] 
The mechanisms of IFN-induced toxicity are unclear but are most likely 
multifactorial. Fatigue is the most common symptom associated with chronic use of 
IFN-α, occurring in more than 70% of patients. It is frequently the dose-limiting 
toxicity. The exact etiology of the fatigue is unclear, but there appears to be both a 
psychological and neuromuscular component. Chronic fatigue generally worsens 
with continued therapy, does not exhibit tolerance, is dose-related, and does not 
respond to therapy with steroids or antiinflammatory drugs. [8] 
Interferon beta is also a very hydrophobic protein and tends to aggregate well. 
This has been shown to reduce activity and productivity. [9] In addition, there is a 
drawback that they have a short half-life and should be administered at frequent 
intervals.  
Therefore, in order to reduce such Limitation, it is necessary to devise an 
administration method which shows a larger effect with a smaller dose. And it is had 
to change the physical characteristics. 
 
3. Protein engineering for overcoming 
５ 
 In a previous study, introduced additional glycosylation into rhIFN-β 1a via site-
directed mutagenesis. Glycoengineering had no effect on rhIFN-β ligand-receptor 
binding, as no loss of specific activity was observed. R27T showed improved 
stability and had a reduced propensity for aggregation and an increased half-life. [10] 
Previously studied recombinant antibody technologies allowed the production of 
antibody-cytokine fusion proteins.[11] Antibody-interferon conjugates can deliver 
lesser amounts of interferons to specific regions of interest at a higher efficiency, 
thereby reducing toxicity and side effects and increasing efficacy. [12] 
In this study, mutagenesis was introduced into the antibody-interferon fusion 
protein in the same way, referring to the results of site-directed mutagenesis in the 
interferon beta. [13] This is thought to contribute to the improvement of low 
productivity and unstable physical properties due to the inherent problem of 
interferon. In order to verify this, we will carry out an experiment to confirm the 
effect due to the antibody, and we will check the interferon signaling to confirm the 
effect caused by the interferon. It could be confirmed by STAT1 phosphorylation, 
activation of the interferon-stimulated response element (ISRE) [14], and activation 
of MHC class I. [15] We will also measure the ability of the fusion protein's 




MATERIALS AND METHODS 
 
1. Construction of a mutated gene by site-directed mutagenesis 
In order to establish a stable cell line and cell that transiently express mutated 
conjugated antibody, pCHO 1.0(Life Technologies) was used as expression vector. 
Among the gene constructs composed of heavy and light chains, the desired 
sequence was changed by site-directed mutagenesis to the heavy chain conjugated 
with carbiferon. This procedure was performed by transferring the heavy chain to 
the pOptiVEC-TOPO Circle vector. The heavy chain gene was cut with AvrII 
(Thermo Scientific, Pittsburgh, PA, USA) and BstZ17I(Thermo Scientific) and 
inserted into the pCHO 1.0 vector. 
 
2. cell lines and culture condition 
Human ovarian carcinoma (OVCAR-3), human gastric carcinoma (NCI-N87), 
human lung carcinoma (A549) cell lines were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). iLite type I IFN assay ready cells 
(U937, ATCC#CRL1593.2) was purchased from the Euro Diagnostica AB (Malmo, 
Sweden) 
OVCAR-3, NCI-N87, A549 and U937 cells were cultured in RPMI-1640 (HyClone, 
７ 
Logan, UT, USA) supplemented with 10% fetal bovine serum (HyClone), 
100units/mL penicillin and 100μg/mL streptomycin. They were grown at 37℃ in a 
humidified 5% CO2 atmosphere. 
 
3. Expression of protein construct in mammalian cells 
The gene encoding Trastuzumab, carbiferon conjugated Trastuzumab and 
carbiferon-C17S conjugated Trastuzumab were transfected into CHO-S cell 
(Thermo Scientific) using the FreeStyleTM MAX reagent (Thermo Scientific). After 
OptiPROTM SFM(Thermo Scientific) was added to FreeStyleTM MAX reagent-DNA 
complex, the mixture was placed on the CHO-S cell cultured in a flask, and the flask 
was incubated at 37℃ in a humidified 8% CO2 atmosphere. 48 hours after 
transfection, proceed directly to select stable transfectants for protein expression. 
The cells are sorted through two selection pressures, by 10~50μg/ml of puromycin 
and 100~1000nM of MTX, in two-phase selection steps. The selected cells are 
cultured with glucose at 37℃ in a humidified 8% CO2 atmosphere and 130RPM for 
14 days to express the proteins. 
 
4. Purification and characterization of conjugated antibody 
８ 
Filtered crude harvests were purified by Protein A affinity chromatography 
(Mabselectsure, GE healthcare). This protein was eluted with 100mM Sodium citrate, 
pH 3.5. Eluted fractions were neutralized immediately with 1.5M Tris-HCl, pH8.8 
and dialyzed in PBS, pH7.4. In the second purification step, ion exchange was 
performed using HiTrap Q FF (GE healthcare) to remove protein and DNA from the 
host cell. This protein was eluted with 20mM Sodium phosphate and 1M NaCl, pH 
7.0. And concentrated using a 50-kDa cut-off Amicon ultra centrifugal filters 
Ultracel (Millipore, MS, USA). To verify protein purifies, SDS-PAGE was 
performed and stained with Coomassie blue. The concentration of this antibody was 
measured by the Cedex bio system (Roche). Finally, size exclusion chromatograph 
was performed using a HiLoadTM 16/600 superdexTM 200pg column at 1ml/min. 
 
5. Antibodies and Western blot analysis 
NCI-N87 cells were treated with rhIFNβ (0.5~50nM/ml), Trastuzumab 
(0.5~50nM/ml), Trastuzumab-R27T (0.5~50nM/ml), or Trastuzumab-C17S-R27T 
(0.5~50nM/ml), and lysed in RIPA lysis buffer (150mM sodium chloride, 1% Triton 
X-100, 1% sodium deoxycholate, 0.1% SDS, 50mM This-HCl [pH 7.5], 2mM EDTA) 
supplemented with a protease inhibitor mixture (Roche) and phosphatase inhibitor 
mixture (Roche). The lysed cells were incubated for 20 min on 4℃ and clarified by 
centrifugation at 14,000 x g for 10 min. the supernatant was collected, and the protein 
９ 
concentrations were determined using BCA protein assay kit (Thermo Scientific) 
according to the manufacturer’s guide. 20 μg of protein were resolved by 10% SDS-
PAGE and transferred to a polyvinyl difluoride membrane (PVDF; BioRad) the 
PVDF membranes were blocked in TBS-Tween20 buffer containing 5% BSA and 
incubated with primary antibodies at 4℃ overnight. The used primary antibodies 
were anti-pSTAT1 (Cell Signaling Technology) and anti-β-actin (Santa Cruz 
Biotechnology). And incubated with second antibodies that anti-mouse IgG-HRP 
(ThermoFisher Scientific) or anti-rabbit IgG-HRP (ThermoFisher Scientific) were 
incubated for 1 hour in room-temperature. And HRP were visualized using Clarity 
Western ECL substrate (Bio-Rad). 
CHO-S cells’ culture fluids expressing Trastuzumab-R27T, or Trastuzumab-C17S-
R27T were subject to 10% SDS-PAGE, and the resolved proteins were transferred 
to a PVDF membrane (Bio-Rad). The PVDF membranes were blocked in TBS-
Tween20 buffer containing 5% skim milk and incubated with anti-human IgG-HRP 
(GenScript). And HRP were visualized using Clarity Western ECL substrate (Bio-
Rad). 
 
6. Interferon β bioactivity analysis by Luciferase assay 
Interferon β bioactivity were measured by Luciferases assays using iLITE type 1 
IFN assay ready cells (Euro Diagnostica) and a Luciferase assay kit (Promega). 
１０ 
iLITE type 1 IFN assay ready cells were seeded to 96-well plates and treated with 
the indicated concentration of rhIFNβ (0.05~5000nM/ml), Trastuzumab 
(0.05~5000nM/ml), Trastuzumab-R27T (0.05~5000nM/ml), or Trastuzumab-C17S-
R27T (0.05~5000nM/ml). After 18 hours, the activities of firefly luciferase were 
determined using a microplate reader (TECAN)  
 
7. Immunomodulatory effect assay by FACS 
The immunomodulatory effects were measured by the activation of MHC Class I in 
A549 cells. A549 cells were seeded to 96-well plates and treated with the indicated 
concentration of Trastuzumab (0.1~1000ng/ml), Trastuzumab-R27T 
(0.1~1000ng/ml), or Trastuzumab-C17S-R27T (0.1~1000ng/ml) for 48 hours. After 
treating the cells with Cell Dissociation Buffer Enzyme-Free PBS-based (Gibco), 
they were collected by centrifugation. Cells were diluted to a concentration of 1 x 
107 cells/mL with FACS buffer and the expression of MHC Class I was measured by 
FACS analysis by BD FACS Caliber system equipped with the Cell Quest Pro 
software (BD Biosciences). FITC anti-human HLA-A, B, C Antibody (BioLegend) 
were used for detection. 
 
8. Anti-proliferation activity 
The anti-proliferation efficacy of Trastuzumab-R27T or Trastuzumab-C17S-R27T 
１１ 
was using viability assays and Calcein-AM assays. 
Viability assays were used Water-Soluble Tetrazolium (WST) colorimetric assay 
(Ez-Cytox; Daeil Lab Service). NCI-N87, OVCAR-3, BT-549 and A549 cells were 
seeded to 96-well plates and treated with the indicated concentration of Trastuzumab 
(0.01~10000ng/ml), Trastuzumab-R27T (0.01~10000ng/ml), or Trastuzumab-C17S-
R27T (0.01~10000ng/ml) for 72 hours. After that, 10μl of WST reagent was added 
to each well, the plates were incubated for 30 min, and absorbance was measured at 
430 nm using a microplate reader (TECAN). 
Calcein-AM assays were used Calcein-AM reagent (BioLegend). NCI-N87, 
OVCAR-3, BT-549 and A549 cells were seeded to 6-well plates and treated with the 
indicated concentration of Trastuzumab-R27T (1~10000ng/ml) or Trastuzumab-
C17S-R27T (1~10000ng/ml) for 72 hours. And treat 10μl of the 1μM Calcein-AM 
working solution. And incubated cells for 20 minutes at 37℃ and keep protected 
from light. After incubation cells in culture medium for 10 minutes, and then 
observed using a Fluorescence Microscope (IX70; Olympus). 
 
9. Flow Cytometry analysis 
Flow cytometry analysis was used to determine the ability of the conjugated antibody 
to bind to HER2. NCI-N87 and BT-549 cells were harvested by Cell Dissociation 
Buffer Enzyme-Free PBS-based (Gibco), blocked for 1 hour at 4℃ in cold 
phosphate-buffered saline (PBS) containing 2% Fetal bovine serum (FBS; HyClone). 
１２ 
The cells were washed three times with PBS, incubated for 30 min at 4℃ with 1μg 
of Trastuzumab, Trastuzumab-R27T or Trastuzumab-C17S-R27T diluted by PBS. 
And the cells were washed three times with PBS, incubated for 30 min at 4℃ with 
Gaot anti Human IgG FITC (Jackson). The cells were identified by detection of 
fluorescent antibodies using a BD FACS Caliber system equipped with the Cell 
Quest Pro software (BD Biosciences). 
 
10. Antibody-dependent cell-mediated cytotoxicity (ADCC) 
assay 
The antibody-dependent cell-mediated cytotoxicity efficacy of Trastuzumab, 
Trastuzumab-R27T or Trastuzumab-C17S-R27T was using LDH assays. NCI-N87 
cells were seeded 2 x 104 cells to 96-well plates and incubated 24 hours. Treated with 
the indicated concentration of Trastuzumab (0.01~10000ng/ml), Trastuzumab-R27T 
(0.01~10000ng/ml), or Trastuzumab-C17S-R27T (0.01~10000ng/ml). After that, 8 
x 104 NK-92MI-CD16 cells were added and incubated 6 hours. Add 10 μl of lysis 
soution to the positive control 1 hour before the measurement. After that, centrifuge 
at 500 g and transfer the supernatant to a new plate in 50 μl increments. Add 50 ul 
of CytoTox 96 reagent (Promega) to the new plate, block the light and incubate for 
30 minutes at room temperature. Stop solution is added in 50 μl increments and 
absorbance is measured at 490 nm within 1 hour using a microplate reader (TECAN). 
１３ 
11. Aggregation assay 
An aggregation assay was performed to measure the physical properties. Dispense 2 
μl of the diluted PROTEOSTAT detection reagent (Enzo). Into the bottom of each 
well of 96-well plate. Add 98 μl of the Trastuzumab-R27T (1mg/ml), or 
Trastuzumab-C17S-R27T (1mg/ml) each well. Light was blocked and incubated at 
room temperature for 15 minutes. Read generated signal with a fluorescence 
microplate reader (TECAN) using an excitation setting of about 500 nm and an 












1. Expression and purification analysis of Trastuzumab-C17S-
R27T fusion protein 
The stable cell line that expresses the antibody continuously was constructed and the 
experiment was conducted. For comparison with the expressed Trastuzumab-C17S-
R27T, Trastuzumab-R27T and Trastuzumab were also expressed and purified under 
the same conditions. Expression was incubated in CHO-S cell line for 10 days at 37 ° 
C, 5% CO2. 
Expressed culture medium was assayed for antibody concentration via Cedex-bio. 
Each culture medium adjusted its concentration to match the conditions as closely as 
possible. Finally, the concentration was adjusted to 80 mg / L. 
Purification was performed using an affinity chromatographic method using an 
AKTA instrument and a protein A bead. In most cases, Trastuzumab-C17S-R27T 
was determined to have high purification efficiency and purity. The purification 
efficiency in the affinity chromatography step was measured within a range of 
maximum 39% to minimum 25%. 
In order to increase the purity, the first purified product was subjected to second 
purification through ion exchange chromatography. In the second purification, 
１５ 
impurities were removed considerably, and high purity could be obtained. However, 
the purification efficiency was relatively low as 11 ~ 17%, and the yield of the final 






























Figure 1. Purification result of Trastuzumab-R27T. (A) This is the result 
of affinity chromatography using protein A bead column. (B) The results of 
ion exchange chromatography using Q-column. Experiments were conducted 
by sampling the fractions corresponding to the peaks. (C) Each refined 
product was sampled and subjected to PAGE under reducing conditions and 
stained with coomassie. (D) Each refined product was sampled and subjected 





























Figure 2. Purification result of Trastuzumab-C17S-R27T. (A) This is the 
result of affinity chromatography using protein A bead column. (B) The 
results of ion exchange chromatography using Q-column. Experiments were 
conducted by sampling the fractions corresponding to the peaks. (C) Each 
refined product was sampled and subjected to PAGE under reducing 
conditions and stained with coomassie. (D) Each refined product was sampled 
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Figure 3. Comparison of purification efficiency of Trastuzumab-R27T 
and Trastuzumab-C17S-R27T. (A) This is a graph comparing the yields of 
the affinity chromatography performed first. (B) This is a graph comparing 
the yields of the second-conducted ion exchange chromatography. (C) Each 
final purified product was treated with PNGase for 2 hours and subjected to 
PAGE under reducing conditions. After the progression, they were identified 











2. IFN bioactivity of Trastuzumab-C17S-R27T 
To confirm the bioactivity of IFN fused to Trastuzumab-C17S-R27T, I used the 
following facts. IFN activity is mediated through the binding of type I IFN receptors 
and the subsequent phosphorylation of STATs. Therefore, I used Trastuzumab-C17S-
R27T as a measure of induction of STAT1 phosphorylation in NCI-N87 cells. The 
results clearly showed that the signal was improved by concentration, and the 
activation level of Trastuzumab-C17S-R27T was superior to that of Trastuzumab-
R27T. 
In another way, I used the iLITE type 1 IFN assay ready cell system to confirm 
the bioactivity of IFN. This cell is a cell that expresses firefly luciferase under the 
control of IFN-responsive promotor. Cells were seeded in 96-well plates in the same 
number and treated with various concentrations of Trastuzumab-C17S-R27T to 
measure their luminescence. The results show that Trastuzumab-C17S-R27T has 
higher overall luminescence when compared to Trastuzumab-R27T, especially at 
intermediate concentrations. 
Immunomodulatory effects were determined by measuring the degree of MHC 
Class I activation in A549 cells. FACS analysis confirmed IFN-inducible expression 
of MHC class I on the surface of A549 cells. The results showed that Trastuzumab-






































1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
1 s t P u r if ic a t io n  A n t ib o d y  L u c ife ra s e  A s s a y
tre a tm e n t a m o u n t (p M )
T ra s tu zu m a b
IF N -b e ta
T ra s tu zu m a b -R 2 7 T











































2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
2 n d  P u r if ic a t io n  A n t ib o d y  L u c ife ra s e  A s s a y




















T ra s tu zu m a b
IF N -R 2 7 T
T ra s tu zu m a b -R 2 7 T
T ra s tu z u m a b -C 1 7 S -R 2 7 T
C
 
Affinity purified protein 
 




Figure 4. IFN bioactivity of Trastuzumab-C17S-R27T. (A) The iLITE cells 
were seeded 1 x 104 in a 96-well plate and the primary purified product was 
treated at various concentrations as follows. After 18 hours, luciferin was 
treated and absorbance was measured. (B) The same procedure was followed 
for the secondary purification results. (C) U937 cells were seeded 5 x 105 in a 
6-well plate and treated with secondary purification products, and after 10, 
30, and 60 minutes, the cells were harvested and subjected to PAGE under 
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Figure 5. IFN induced immunomodulatory activity of Trastuzumab-
C17S-R27T 
(A) A549 cells were seeded 5 x 105 in a 6-well plate and treated with various 
concentrations of fusion proteins and analyzed by FACS using anti-human 
HLA A, B, C antibodies. (B) The results of the FACS analysis are shown 
graphically. (C) The fusion protein was subjected to secondary purification 












3. Targeting of ERBB-2 by Trastuzumab-C17S-R27T 
FACS was used to confirm binding ability to ERBB-2. In ERBB-2 positive cells, 
Trastuzumab, Trastuzumab-R27T, and Trastuzumab-C17S-R27T all showed 
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Figure 6. Analysis of ERBB-2-targeting function by FACS.   
(A) FACS analysis was performed using anti-human IgG antibody after 
treating the fusion protein with NCI-N87, HER2 positive cell, for 1 hour. 
(B) FACS analysis was performed on ERBB-2 negative cells BT-549 under 
the same conditions. (C), (D) The same assay was performed using cell lines 

















4. Anti-cancer efficacy of Trastuzumab-C17S-R27T 
In this experiment, anti-cancer effect was confirmed by two methods. After 72 
hours, the number of living cells was measured using WST. The results showed a 
boiling killing effect in NCI-N87 cells, and more efficacy in Ovcar-3 cells. In the 
negative control group, no killing effect was observed. 
Four cell lines were treated with the same fusion protein and fluorescently imaged 
live cells by staining with Calcein-AM. Similar to the results of WST, NCI-N87 
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３２ 
Figure 7. In vitro anti-cancer efficacy by WST assay   
(A) NCI-N87, ERBB-2-positive cells, was seeded 1 x 104 in a 96-well plate 
and, treated with various concentrations of fusion protein 1 day later, and WST assay 
was performed after 2 days. (B) The same experiment was performed on BT-
549, ERBB-2- negative cells, under the same conditions. (C) and (D), The 






Figure 8. In vitro anti-cancer efficacy by Calcein-AM staining    
Each cell was seeded in a 6-well plate and the fusion protein was treated at 
different concentrations and incubated for 2 days. After that, staining was 
performed using Calcein-AM and observed with a fluorescence microscope. 
 
３４ 
5. ADCC efficacy of Trastuzumab-C17S-R27T 
induced cell-mediated cytotoxicity induced by Trastuzumab. Experiments were 
performed on ERBB-2 positive cells NCI-N87 and ERBB-2 negative cells BT549 
and effector cells NK-92MI-CD16. In NCI-N87 cells, all three proteins showed 
similar efficacy. The protein treatment time was as short as 6 hours, suggesting that 
the immunopotentiating effect of interferon did not appear well. 



































Figure 9. In vitro ADCC efficacy of Trastuzumab-C17S-R27T 
(A) NCI-N87, ERBB-2-positive cell, was seeded 1 x 104 in 96-well plate and 
the fusion protein and effector cell NK-92MI-CD16 cells were treated and 
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cells, was seeded in a 96-well plate and the fusion protein and effector cell 


















This study compared and analyzed the properties of proteins substituted with 
serine for cysteine. We set two hypotheses for the effect of this substitution. The first 
is the improvement of physical properties. The substituted proteins showed higher 
purification efficiency and the active ingredient content in the affinity 
chromatography, and the purified products showed the same or higher efficacy at the 
same concentration. This is presumably due to the possibility that the free-SH groups 
of cysteine may interact with each other, by replacing cysteine with serine to turn the 
free-SH group into an -OH group to block the formation of disulfide bonds. It is 
considered that the formation of such a disulfide bond in the purification process 
may lower the yield. In fact, the purification efficiency was improved in the form of 
replacing cysteine with serine. However, due to the nature of interferon, the 
purification efficiency is lower than that of pure antibodies. Through secondary 
purification through ion exchange chromatography, impurities can be reduced and 
the purity of the protein with an effective structure can be further increased, and the 
second purified protein exhibits the same or higher efficacy than the first purified 
protein. However, there is a tendency for higher aggregation to occur due to the 
higher concentration of interferon mutants in the higher effective structure. 
Second, it is the improvement of the efficacy by improvement of physical 
properties. If the individual interferon mutants in the active state are increased due 
３８ 
to the improvement in physical properties, a higher effect can be observed when the 
same concentration of the fusion protein is administered. The results of the 
experiments support this hypothesis. In the experiment with the effect of the antibody 
as the main variable, the results of administration based on the antibody 
concentration were similar. On the other hand, in experiments in which the effect of 
interferon mutants was the main variable, the efficacy of the fusion protein with the 
substituted interferon mutant increased significantly when administered based on the 
antibody concentration. This is thought to be due to the presence of more interferon 
with more activity. However, when analyzing the results after ion exchange 
purification, this tendency disappears and the two proteins show almost equal 
efficacy. This is because the ratio of 55 kDa to 90 kDa contained in the result of the 
affinity purification is different in the two proteins, but the protein having an ion 
exchange purification has a protein around 90 kDa. 
In addition, the ADCC-confirmed experiment showed a slight decrease in the 
ADCC effect of the interferon-linked protein. This suggests that interferon is linked 
to the Fc region of the antibody and may interfere with physical binding. Therefore, 
ADCC can be further improved by further adjusting the length of the linker. 
In a FACS experiment to observe ERBB-2 targeting, it was observed that 
Trastuzumab-R27T and Trastuzumab-C17S-R27T treated with ERBB-2 showed a 
greater shift than Trastuzumab in the low cell line. This is probably due to the 
interferon part of Trastuzumab-R27T and Trastuzumab-C17S-R27T interacting with 
the interferon receptor. In addition, Trastuzumab-R27T slightly shifted compared to 
３９ 
Trastuzumab-C17S-R27T, suggesting that there may be interactions between 
interferons in Trastuzumab-R27T. 
Therefore, when the results of this experiment are applied, higher productivity and 
higher effect can be obtained, which may be useful in industrial aspects and 
economical aspects. However, the inherent toxicity problem of interferon beta is 
expected to require additional confirmation experiments. As the efficacy increases, 
the toxicity may increase as well. In order to reduce the toxicity of interferon, it is 
considered to form an antibody in the form of a heterodimer which binds an 
















인터페론 베타는 암세포의 사멸을 유도할 수 있어 항암제로 관심을 
받고 있다. 그러나 인터페론 베타는 낮은 단백질 안정성과 투여 후 
전신독성의 유발, 암세포의 저항성은 인터페론 베타를 항암제로 
사용하는데 있어서 제한되고 있다. 이를 극복하기 위해서 항체와 
융합단백질을 만드는 시도가 이루어지고 있다. 선행연구에서 본 
연구그룹은 80번 아미노산에 N-glycosylation을 가지고 있는 재조합 인간 
인터페론 베타1a(rhIFNβ-1a)의 27번 아미노산인 Arginine을 Threonine으로 
치환하여 25번 아미노산에 추가적인 Glycosylation을 유도한 rhIFNβ-1a을 
개발하였고 R27T로 명명하였으며, 이를 다시 항-ERBB-2 치료용 항체인 
Trastuzumab에 융합시킨 융합단백질에 관한 개발연구를 진행하였다. 
여기에 추가로 물성과 정제 효율성을 개선하기 위하여 융합단백질의 
rhIFNβ-1a 부위의 17번 아미노산인 Cysteine을 Serine으로 치환한 
Trastuzumab-C17S-R27T를 연구개발 하였다.  
본 연구는 Protein A와 Ion exchange를 이용한 정제에서 Trastuzumab-
R27T와 Trastuzumab-C17S-R27T의 정제 효율과 생물 활성을 비교 
분석하였으며, 다양한 암세포주에서 Trastuzumab-R27T와 Trastuzumab-
４１ 
C17S-R27T의 인터페론 생물 활성과 Immunomodulatory 효능, 항암 효능, 
HER2에 결합하는 능력, ADCC 효능 등을 확인하였다.  Trastuzumab-C17S-
R27T는 Trastuzumab-R27T와 비교하였을 때, 정제 효율이 향상되었고, 
항암 효과 및 인터페론 생물 활성과 Immunomodulatory 효능에서도 
동등함을 확인하였다. 추가로 HER2에 결합하는 능력, ADCC 효능들도 
Trastuzumab-R27T와 동등하게 나타났다.  
따라서 Cysteine을 Serine으로 치환한 Trastuzumab-C17S-R27T는 기존 
Trastuzumab-R27T를 대체하여 더욱 효율적인 항암제로서의 활용 가치가 
확인되었다. 
 
주요어 : 인터페론, Trastuzumab-C17S-R27T, 면역치료, 항체치료제, 항암, 
융합단백질, Trastuzumab 
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